Potent Efficacy of Computer-Aided Designed Peptide Degrader Drug on PCSK9-Mediated Hypercholesterolemia
June 2025
TLDR Cadd4 effectively reduces cholesterol levels without side effects.
The study presents Cadd4, a computer-aided designed peptide degrader, as a novel approach to manage hypercholesterolemia by targeting PCSK9, a regulator of LDL receptor degradation. Cadd4 demonstrated effective intracellular delivery and selective degradation of PCSK9 in human LX-2 cells and high-fat diet-induced hypercholesterolemic mouse models. This led to a 38% reduction in hepatic PCSK9 expression, a 25% decrease in total plasma cholesterol, and a 29% reduction in LDL-C levels, with no observed liver toxicity or adverse effects. The findings highlight Cadd4's potential as a cost-effective and scalable therapy for hypercholesterolemia, addressing limitations of current PCSK9-targeted treatments.
